Biosense Webster and Medtronic Form Strategic Alliance to Advance Care for Patients with Cardiac Arrhythmias.Program to Focus on Advancing Clinical Trials, Technology and Education for Electrophysiologists DIAMOND BAR, Calif. & MINNEAPOLIS -- Biosense Webster, Inc. the world leader in cardiac mapping and ablation ablation /ab·la·tion/ (-shun) 1. separation or detachment; extirpation; eradication. 2. removal or destruction, especially by cutting. ab·la·tion n. , and Medtronic, Inc. (NYSE NYSE See: New York Stock Exchange :MDT MDT abbr. Mountain Daylight Time MDT (in the US and Canada) Mountain Daylight Time MDT n abbr (US) (= mountain daylight time) → ), the world leader in implanted cardiac rhythm Noun 1. cardiac rhythm - the rhythm of a beating heart heart rhythm regular recurrence, rhythm - recurring at regular intervals atrioventricular nodal rhythm, nodal rhythm - the normal cardiac rhythm when the heart is controlled by the devices, today announced plans to collaborate on a clinical trial, educational initiatives and a product development program, all of which are aimed at advancing the care of patients with cardiac arrhythmias cardiac arrhythmia n. See cardiac dysrhythmia. Cardiac arrhythmia An irregular heart rate or rhythm. Mentioned in: Holter Monitoring, Stress Test cardiac arrhythmia , also known as irregular heartbeats. The initiative was announced today to coincide with the start of Heart Rhythm Noun 1. heart rhythm - the rhythm of a beating heart cardiac rhythm regular recurrence, rhythm - recurring at regular intervals atrioventricular nodal rhythm, nodal rhythm - the normal cardiac rhythm when the heart is controlled by the 2007, the Heart Rhythm Society's 28th Annual Scientific Sessions, taking place in Denver May 9-12. Heart Rhythm 2007 is the premier medical and scientific conference for electrophysiologists. "We are pleased to collaborate with Medtronic in this important endeavor," said Roy Tanaka, President, Biosense Webster, Inc. "This new strategic alliance will leverage the unique resources and technologies of the two companies together, and will benefit the millions of patients who suffer from cardiac arrhythmias around the world." Under the terms of the agreement, the two companies plan to collaborate on three key areas of interest - a clinical trial, a technology development initiative and educational programs. The companies intend to design the clinical trial to create a new care pathway for identifying candidates most likely to have a successful ablation treatment outcome and increase the acceptance of ablation therapy ablation therapy See Ablation–cardiology. . "Medtronic is intently focused on researching and exploring ways to utilize existing or new technologies for electrophysiologists to better identify and treat patients with cardiac arrhythmias," said Steve Mahle, President of Medtronic's Cardiac Rhythm Disease Management business. "This collaboration will begin by bringing the unique competencies of imaging and navigation together with diagnostics and monitoring in an effort to improve the electrophysiologist's capability in identifying and treating patients. We look forward to collaborating with Biosense Webster to deliver exciting results for our customers." In addition, the two companies will work together to advance patient care through a joint research and development program. The companies plan to integrate specific technologies to provide novel, new solutions for the treatment of complex cardiac arrhythmias. Lifetime education of physicians is a hallmark of both Biosense Webster and Medtronic. Through this relationship, the companies will collaborate to combine resources to extend existing educational opportunities as well as create new instructional programs for electrophysiologists and allied health professionals who work in the arrhythmias field. "With Biosense Webster, we can continue our commitment to education of physicians at all stages of their career," said Mahle. "The field of electrophysiology electrophysiology /elec·tro·phys·i·ol·o·gy/ (-fiz?e-ol´ah-je) 1. the study of the mechanisms of production of electrical phenomena, particularly in the nervous system, and their consequences in the living organism. 2. is always changing and advancing and it is vital that physicians and other health care professionals who work in this field are up-to-date on the latest technologies designed to help patients." About Medtronic Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. About Biosense Webster Biosense Webster Inc, a Johnson & Johnson Company, (www.biosensewebster.com) pioneered EP diagnostic catheters more than 30 years ago and continues to lead the industry as an innovative provider of advanced diagnostic, therapeutic, and mapping tools. As the leader in navigation systems A GPS-based electronic system in a car or truck that provides a real time map of the vehicle's current location as well as step-by-step directions to a programmed destination. See GPS and vehicle tracking. , Biosense Webster's technology includes the largest installed base of navigation systems worldwide in leading hospitals and teaching institutions. With proprietary products such as the CARTO CARTO Cartographic Information Division ([R]) XP System, the CARTOSOUND([TM]) Image Integration Software Module, the THERMOCOOL([R])Irrigated Tip Catheter and the LASSO([R]) Circular Variable Mapping Catheter, the company is changing the way electrophysiologists diagnose and treat arrhythmias. Any forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended April 28, 2006. Actual results may differ materially from anticipated results. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion